| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UH3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 3 | NIH | 10/29/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UH3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 001 | 3 | NIH | 6/6/2024 | $0 |
| | 2024 | 2023 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UH3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 3 | NIH | 1/11/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,038,312 ) |
| | 2023 | 2023 | EPIODYNE INC | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R44DA056336 | Development of an oral analgesic with reduced liabilities | 000 | 2 | NIH | 3/29/2023 | $1,488,866 |
| | 2023 | 2023 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UH3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 3 | NIH | 8/14/2023 | $1,549,446 |
| | 2023 | 2019 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UG3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 1 | NIH | 11/14/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,605,680 ) |
| | 2022 | 2022 | EPIODYNE INC | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UH3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 2 | NIH | 9/15/2022 | $2,594,546 |
| | 2022 | 2022 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R44DA056336 | Development of an oral analgesic with reduced liabilities | 000 | 1 | NIH | 4/6/2022 | $1,011,134 |
|
| Issue Date FY: 2020 ( Subtotal = -$3,252 ) |
| | 2020 | 2019 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UG3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 1 | NIH | 9/22/2020 | $0 |
| | 2020 | 2018 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43DA047723 | Structure-based Optimization of Novel Analgesics without Reinforcing Liabilities | 000 | 1 | NIH | 3/23/2020 | -$3,252 |
|
| Issue Date FY: 2019 ( Subtotal = $6,461,202 ) |
| | 2019 | 2019 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | UG3DA049598 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | 000 | 1 | NIH | 9/23/2019 | $6,461,202 |
|
| Issue Date FY: 2018 ( Subtotal = $300,000 ) |
| | 2018 | 2018 | EPIODYNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43DA047723 | Structure-based Optimization of Novel Analgesics without Reinforcing Liabilities | 000 | 1 | NIH | 8/15/2018 | $300,000 |
|
|
